15.25 – 16.05 jeroen van der laak - How artificial intelligence may change the way pathologists work
Recent research has shown the large potential of artificial intelligence for analysis of digitized histopathological slides. This field of research, often referred to as 'computational pathology', may offer solutions for the challenges that pathologists face, now and in the near future. Computational pathology may relieve the pathologists' workload by automating routine tasks (e.g. tumor detection in biopsies, assessment of tumor size and distance to surgical margins). Expectedly, the first algorithms of this kind will be commercially available within the next few years. In addition, the increased complexity of histopathological diagnostics required for personalized healthcare may be facilitated by automated assessment of tumor grade and other morphological biomarkers (e.g. tumor-stroma-ratio, tumor budding) as well as by identification of morphological biomarkers not accessible by the human eye.
CV Jeroen van der Laak is associate professor in computational Pathology at the Department of Pathology of the Radboud University Medical Center in Nijmegen, The Netherlands and guest professor at the Center for Medical Image Science and Visualization (CMIV) in Linkoping, Sweden. His research focuses on the use of machine learning for the analysis of whole slide images. Application areas include: improvement of routine pathology diagnostics, objective quantification of immunohistochemical markers, and study of novel imaging biomarkers for prognostics. Dr van der Laak has an MSc in computer science and acquired his PhD from the Radboud University in Nijmegen. He co-authored over 95 peer-reviewed publications and is member of the editorial boards of Laboratory Investigation and the Journal of Pathology Informatics. He is member of the board of directors of the Digital Pathology Association and organizer of sessions at the European Congress of Pathology and the Pathology Visions conference. He coordinated the highly successful CAMELYON grand challenges in 2016 and 2017. Dr van der Laak acquired research grants from the European Union and the Dutch Cancer Society, among others.